↑ Quigley, Eamonn M.M. (2013). “Treatment level 1”. Irritable Bowel Syndrome: Diagnosis and Clinical Management . Chichester, West Sussex: Wiley-Blackwell. ISBN9781118444740. Bản gốc lưu trữ ngày 8 tháng 9 năm 2017.
1 2 Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). “Costs of irritable bowel syndrome in the UK and US”. PharmacoEconomics. 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID16445300.
1 2 Hulisz D (2004). “The burden of illness of irritable bowel syndrome: current challenges and hope for the future”. J Manag Care Pharm. 10 (4): 299–309. PMID15298528.
1 2 Whitehead WE, Palsson O, Jones KR; Palsson; Jones (2002). “Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?”. Gastroenterology. 122 (4): 1140–56. doi:10.1053/gast.2002.32392. PMID11910364.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Mayer EA (2008). “Clinical practice. Irritable bowel syndrome”. N. Engl. J. Med. 358 (16): 1692–9. doi:10.1056/NEJMcp0801447. PMID18420501. Đã bỏ qua tham số không rõ |month= (trợ giúp); |ngày truy cập= cần |url= (trợ giúp)
↑ Bercik P, Verdu EF, Collins SM; Verdu; Collins (2005). “Is irritable bowel syndrome a low-grade inflammatory bowel disease?”. Gastroenterol. Clin. North Am. 34 (2): 235–45, vi–vii. doi:10.1016/j.gtc.2005.02.007. PMID15862932.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Quigley EM (2005). “Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?”. Chinese journal of digestive diseases. 6 (3): 122–32. doi:10.1111/j.1443-9573.2005.00202.x. PMID16045602.
↑ Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES; Axelsson; Gillberg; Abrahamsson; Svedlund; Björnsson (2002). “Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors”. Am. J. Gastroenterol. 97 (2): 389–96. doi:10.1111/j.1572-0241.2002.05475.x. PMID11866278.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ; Oldenburg; Wismeijer; Van Berge Henegouwen; Smout (2004). “IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior”. Dig. Dis. Sci. 49 (3): 469–74. doi:10.1023/B:DDAS.0000020506.84248.f9. PMID15139501.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe L; Ruigómez; Wallander; Johansson; Olbe (2000). “Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome”. Scand. J. Gastroenterol. 35 (3): 306–11. doi:10.1080/003655200750024191. PMID10766326.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Paré P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR; Gray; Lam; Balshaw; Khorasheh; Barbeau; Kelly; McBurney (2006). “Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study”. Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID17157129.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). “Costs of irritable bowel syndrome in the UK and US”. PharmacoEconomics. 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID16445300.Quản lý CS1: nhiều tên: danh sách tác giả (liên kết)
↑ Boivin M (tháng 10 năm 2001). “Socioeconomic impact of irritable bowel syndrome in Canada”. Can. J. Gastroenterol. 15 (Suppl B): 8B–11B. PMID11694908.
